SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.

Shaanxi Kanghui Pharmaceutical Co., Ltd.

603139

CNE100002XT3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
14.4 ^CNY	-0.96%		-12.94%	-23.28%

Apr. 26	Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 15	Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback	MT

Hubei Klavi Biopharmaceutical Co., Ltd. announced that it has received CNY 50.4 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. and other investors

July 29, 2020

On July 30, 2020, Hubei Klavi Biopharmaceutical Co., Ltd. closed the transaction.

Latest news about Shaanxi Kanghui Pharmaceutical Co., Ltd.

Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback	Mar. 15	MT
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal	Nov. 24	MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs	23-10-17	MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Sichuan Chunsheng Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 56.795265 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	22-11-28	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. completed the acquisition of an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership).	21-12-13	CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	21-12-13	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. agreed to acquire an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership) for CNY 30 million.	21-12-10	CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	21-12-09	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-22	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-27	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. acquired 51% stake in Shandong Youbang Biochemical Technology Co., Ltd. from Lai Xinsheng for CNY 32.6 million.	20-09-23	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-18	CI
Hubei Kelaiwei Biopharmaceutical Co., Ltd. announced that it has received funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	20-07-30	CI
Hubei Klavi Biopharmaceutical Co., Ltd. announced that it has received CNY 50.4 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. and other investors	20-07-29	CI
Hubei Klavi Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 50.4 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. and other investors	20-07-20	CI

Chart Shaanxi Kanghui Pharmaceutical Co., Ltd.

Duration

Period

Chart Shaanxi Kanghui Pharmaceutical Co., Ltd.

More charts

SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. is principally engaged in research and development, manufacture and sales of Chinese patent medicines. The Company's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The Company distributes its products just within China domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.	-23.28%	199M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals

Shaanxi Kanghui Pharmaceutical Co., Ltd.

Equities

603139

CNE100002XT3

Pharmaceuticals

Hubei Klavi Biopharmaceutical Co., Ltd. announced that it has received CNY 50.4 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. and other investors

Latest news about Shaanxi Kanghui Pharmaceutical Co., Ltd.

Chart Shaanxi Kanghui Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Sector Generic Pharmaceuticals